Trastuzumab

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.


Cat. No.: EX-A4357	Purity: >98%

	Chemical structure of Trastuzumab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	785	In-stock
50mg	1185	In-stock
100mg	2085	In-stock
200mg	2885	In-stock
1g	Get quote

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Anti HER2, Ig gamma-1 chain C region
Synonyms 2	Recombinant humanized anti-HER2 antibody
CAS No.	180288-69-1
Purity	>98%
Formula	C6470H10012N1726O2013S42
Mol Weight	145531.5
Appearance	colourless to light yellow (liquid)
Shelf Life	>3 years if stored properly
Storage	Pure -30℃ 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. Shipping with ice bag upon request

Reference:	[1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. [2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. [3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.
CoA	CoA of Trastuzumab


		Search